NYSE:PRME Prime Medicine (PRME) Stock Price, News & Analysis $2.47 +0.05 (+2.07%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Prime Medicine Stock (NYSE:PRME) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Prime Medicine alerts:Sign Up Key Stats Today's Range$2.41▼$2.6950-Day Range$1.17▼$2.6552-Week Range$1.11▼$6.75Volume3.23 million shsAverage Volume1.50 million shsMarket Capitalization$324.30 millionP/E RatioN/ADividend YieldN/APrice Target$10.08Consensus RatingModerate Buy Company OverviewPrime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.Read More… Prime Medicine Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks75th Percentile Overall ScorePRME MarketRank™: Prime Medicine scored higher than 75% of companies evaluated by MarketBeat, and ranked 262nd out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingPrime Medicine has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoveragePrime Medicine has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Prime Medicine's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Prime Medicine are expected to grow in the coming year, from ($1.68) to ($1.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Prime Medicine is -1.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Prime Medicine is -1.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPrime Medicine has a P/B Ratio of 1.80. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted35.77% of the float of Prime Medicine has been sold short.Short Interest Ratio / Days to CoverPrime Medicine has a short interest ratio ("days to cover") of 8.3.Change versus previous monthShort interest in Prime Medicine has recently increased by 2.84%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthWeak Dividend YieldPrime Medicine does not currently pay a dividend.Dividend GrowthPrime Medicine does not have a long track record of dividend growth.Read more about Prime Medicine's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted35.77% of the float of Prime Medicine has been sold short.Short Interest Ratio / Days to CoverPrime Medicine has a short interest ratio ("days to cover") of 8.3.Change versus previous monthShort interest in Prime Medicine has recently increased by 2.84%, indicating that investor sentiment is decreasing. News and Social Media2.5 / 5News Sentiment1.45 News SentimentPrime Medicine has a news sentiment score of 1.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Prime Medicine this week, compared to 3 articles on an average week.Search InterestOnly 8 people have searched for PRME on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Prime Medicine to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership5.0 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Prime Medicine insiders have bought more of their company's stock than they have sold. Specifically, they have bought $110,250.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders22.93% of the stock of Prime Medicine is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions70.37% of the stock of Prime Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Prime Medicine's insider trading history. Receive PRME Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prime Medicine and its competitors with MarketBeat's FREE daily newsletter. Email Address PRME Stock News HeadlinesPrime Medicine, Inc. (NYSE:PRME) Major Shareholder David R. Liu Purchases 21,000 SharesJune 24, 2025 | insidertrades.comPrime Medicine, Inc. (NYSE:PRME) Major Shareholder Acquires $31,290.00 in StockJune 17, 2025 | insidertrades.comWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how to trade it, this phase brings the most potential. We’re now in that window. A free workshop outlines how a proven system is targeting daily wins, passive income, and explosive upside through curated altcoin picks. Whether you're new to crypto or looking to catch the next move with confidence, this is your roadmap. And just for showing up, you’ll receive $10 in real Bitcoin. Don’t miss it.June 30 at 2:00 AM | Crypto Swap Profits (Ad)Head to Head Survey: Voyager Therapeutics (NASDAQ:VYGR) vs. Prime Medicine (NYSE:PRME)June 20, 2025 | americanbankingnews.comPrime Medicine’s Technological Edge and Strategic Positioning Highlighted as Key Investment OpportunityJune 17, 2025 | tipranks.comPrime Medicine to Participate in Upcoming Investor ConferencesMay 29, 2025 | globenewswire.comCitigroup Downgrades Prime Medicine (PRME)May 28, 2025 | msn.comCiti Downgrades Prime Medicine (PRME) to Neutral, Cuts PT to $1.50 Due to Market UncertaintyMay 27, 2025 | msn.comSee More Headlines PRME Stock Analysis - Frequently Asked Questions How have PRME shares performed this year? Prime Medicine's stock was trading at $2.92 at the start of the year. Since then, PRME stock has decreased by 15.4% and is now trading at $2.47. View the best growth stocks for 2025 here. How were Prime Medicine's earnings last quarter? Prime Medicine, Inc. (NYSE:PRME) posted its quarterly earnings data on Friday, March, 7th. The company reported ($1.65) EPS for the quarter. When did Prime Medicine IPO? Prime Medicine (PRME) raised $175 million in an initial public offering on Thursday, October 20th 2022. The company issued 10,294,118 shares at $16.00-$18.00 per share. How do I buy shares of Prime Medicine? Shares of PRME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Prime Medicine own? Based on aggregate information from My MarketBeat watchlists, some other companies that Prime Medicine investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), Intel (INTC), NVIDIA (NVDA), Meta Platforms (META) and Advanced Micro Devices (AMD). Company Calendar Last Earnings3/07/2025Today6/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNYSE:PRME CIK1894562 Webprimemedicine.com Phone617-564-0013FaxN/AEmployees234Year FoundedN/APrice Target and Rating Average Stock Price Target$10.08 High Stock Price Target$18.00 Low Stock Price Target$1.50 Potential Upside/Downside+289.3%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$198.13 million Net MarginsN/A Pretax Margin-27,406.12% Return on Equity-107.87% Return on Assets-74.97% Debt Debt-to-Equity RatioN/A Current Ratio6.50 Quick Ratio6.50 Sales & Book Value Annual Sales$3.85 million Price / Sales88.42 Cash FlowN/A Price / Cash FlowN/A Book Value$1.37 per share Price / Book1.89Miscellaneous Outstanding Shares131,294,000Free Float100,378,000Market Cap$340.05 million OptionableOptionable Beta1.55 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NYSE:PRME) was last updated on 6/30/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredConsumer apocalypse imminent (7 ominous red flags)The #1 Gold play right now (not a miner, ETF, or bullion) Gold is up 237% since 2008... but one gold invest...Stansberry Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prime Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Prime Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.